Shkreli Gives US Congress Cold Shoulder

Martin Shkreli, the 32-year-old former CEO of Turing Pharmaceuticals who made negative headlines last year after jacking up the price of the toxmoplasmosis drug Daraprim (pyrimethamine) from $13.50 to $750 a pill immediately after acquiring marketing rights, has refused to testify before a US Congressional committee.

The oversight committee of the House of Representatives is investigating Turing’s drug price hikes.

Shkreli invoked the Fifth Amendment to the US constitution, the right to remain silent. Instead of answering questions, the executive also facing charges of fraud in a US federal court in New York made headlines again by hurling insults at the assembled members of the committee.

At the hearing, the lawmakers released excerpts from a reported 250,000 documents said to show that Shkreli sought to make $1 billion in profit from selling the 62-year-old drug at the higher price.

The committee’s highest-ranking Democratic member, Maryland congressman Elijah Cummings, said that since acquiring Daraprim in August 2015 Turing took in $98 million in revenue.

This was despite the fact that the drug – available only on the US market – was out of reach for most people with compromised immune systems, such as HIV sufferers and pregnant women.

In December 2015, Express Scripts Holding, the biggest pharmacy benefits manager in the US, said it planned to list Imprimis Pharmaceuticals’ cheaper alternative to Daraprim for $1 per pill.

The US Federal Bureau of Investigation, FBI, is currently investigating Shrekli’s wider financial dealings. The 32-year-old stands accused of running a Ponzi scheme at drugmaker Retrophin and at a hedge fund, MSMB Capital Management, both of which he headed.

Retrophin meanwhile has agreed to pay $3 million to settle a class action lawsuit that accuses it of failing to disclose its former CEO’s actions. The suit was filed in 2014, the same year that Shkreli was fired from the company.

The proposed settlement would also resolve the related claims against Shkreli in his role as CEO. While in the position he is accused of siphoning off $11 million in assets to pay off defrauded investors from the failed hedge fund. The company’s current management has disputed the charges.

A federal judge in Manhattan has given preliminary approval to the settlement and will hold a hearing on June 10 to decide whether to give the final green light.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.